Brainstorm Cell Therapeutics


Maxim Reiterates Buy On Brainstorm As It Wins Patent Approval In Israel

Maxim Group analyst Jason Kolbert came out with an update on Brainstorm Cell Therapeutics (NASDAQ:BCLI), as the company announced that it received a Notice of Allowance from …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts